48 results on '"Yang, Guangli"'
Search Results
2. Data from CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
3. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
4. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
5. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
6. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
7. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
8. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
9. Data from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
10. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
11. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
12. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
13. Data from CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
14. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
15. Data from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
16. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
17. Supplementary Methods and Figures S1 to S7 from CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
18. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
19. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
20. Supplementary Figure from Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents
21. Supplementary Table 4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
22. Supplementary Table 2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
23. Supplementary figure S4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
24. Supplementary Table 1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
25. Supplementary Methods and Figure Legends from Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
26. Supplementary Figure S3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
27. Supplementary Table 3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
28. Supplementary Table 1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
29. Supplementary Table 3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
30. Supplementary Figure S2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
31. Supplementary Table 2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
32. Supplementary Figure S1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
33. Supplementary Figure S2 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
34. Supplementary Figures 1-3 from Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
35. Supplementary Figure S3 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
36. Supplementary Methods and Figure Legends from Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
37. Supplementary Table 4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
38. Supplementary figure S4 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
39. Supplementary Figures 1-3 from Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
40. Supplementary Figure S5 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
41. Supplementary Figure S5 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
42. Supplementary Figure S1 from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
43. Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125 Selective Agents
44. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
45. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
46. Abstract 4975: A small molecule pan Id protein antagonist shows strong antitumor activity
47. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
48. An 19F Magnetic Resonance–Based In Vivo Assay of Solid Tumor Methotrexate Resistance: Proof of Principle
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.